Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Stefan Geschwindner, PhD (he/him/his)

AstraZeneca R&D Gothenburg, Vastra Gotaland, Sweden

Dr. Stefan Geschwindner, currently Director and Head of Biophysics at AstraZeneca R&D Gothenburg in Sweden, has established a distinguished career in the field of biophysics. He earned his Ph.D. from the University of Frankfurt, specializing in NMR techniques for unraveling protein structures. Subsequently, his journey led him to the Astra Structural Chemistry Laboratory, where he focused initially on protein engineering whilst implementing a set of diverse biophysical methods.
Having held prior roles as Team Leader in Protein Engineering and Principal Scientist in Biophysics, Dr. Geschwindner has been a consistent practitioner of biophysical methods over the past two decades. His expertise extends to enhancing the mechanistic understanding of protein-ligand interactions and kinetics as well as their thermodynamics, with significant contributions to FBLG approaches.
In his current capacity, he leads the Biophysics department at AstraZeneca R&D Gothenburg. This team is dedicated to supporting projects spanning cardiovascular, renal, and metabolic disease areas, as well as respiratory, inflammation and rare disease areas. Engaging in a wide array of activities, the team executes fragment-based lead generation screening, actively participates in hit validation including platforms like HTS and DNA-encoded libraries, and endeavors to generate a deep mechanistic understanding of target systems and their modulation by both small and large drug molecules.
Notably, Dr. Geschwindner's team employs advanced structural techniques such as HDX-MS and NMR to glean structural information critical for driving drug design and selection. Their multifaceted approach reflects a comprehensive commitment to advancing the field of drug discovery and development, positioning his team at the forefront of innovative and impactful research in drug discovery. His leadership in the area of Biophysics is evidenced by his authorship and co-authorship of over 50 publications, book chapters, and patents leading to an h-index of 27, all highlighting the substantial impact of biophysical approaches in drug discovery.

Disclosure information not submitted.

Presentation(s):